Type/Product Area

Terms/Details (Date)


Hyaluron Contract Manufacturing*

Agreement to manufacture ANX-514 for preclinical and clinical studies

Adventrx intends to seek FDA guidance regarding a 505 b)(2) regulatory path for the product and will start a marketing- enabling trial later this year(4/5)


Pharmatek Laboratories Inc.*

Manufacturing agreement for Adventrx's ANX-201 (Thiovir) capsules for clinical studies

Phase I/II combination trials in HIV patients are expected to begin in the third quarter (3/20)

Aldagen Inc.*

StemCell Technologies Inc.*

Worldwide distribution agreement under which StemCell will distribute Aldagen's Aldecount product

Terms of the deal were not disclosed (3/2)

Alteon Inc.

OXIS International Inc. (OTC BB:OXIS)

Expanded license agreement under which Alteon picks up exclusive worldwide rights to ALT- 074 and all related organoselenium compounds in OXIS' library for development and commercialization in all indications

Alteon agreed to invest at least $7.5M in OXIS over a three-year period; the deal also includes milestone payments to OXIS, plus any sublicensing fees or royalties; Alteon also will make an equity investment for net proceeds of $500,000 (4/9)

Antisoma plc


Agreement to begin the aseptic manufacturing of the cancer drug AS1411

Microtest will handle formulation and aseptic fill/finish of AS1411 material supply for upcoming Phase II trials and will be responsible for stability testing of the compound (3/26)


Stem Cell Sciences KK (joint venture between Stem Cell Sciences Ltd., Australia, LSE:STEM;and Sosei Co. Ltd., Japan)

License agreement covering technologies for myoblast cell implantation to treat stress urinary incontinence

Celogos has granted SCSKK exclusive rights to commercialize in Japan therapeutic products related to myoblast implantation (2/21)**

Cepheid Inc.

VWR International*

Agreement to distribute Cepheid Industrial life science products in the U.S.

The nonexclusive deal expands Cepheid's industrial market reach by extending its domestic sales channel; financial terms were not disclosed (4/17)

Clinical Data

Epigenomics AG (Germany; FSE:ECX)

Agreement for Clinical Data's Cogenics service division to offer the DNA methylation services of Epigenomics

Epigenomics also will promote Cogenics' pharmacogenomics and molecular biology services to its DNA methylation biomarker development partners and customers (4/12)

Cobra Biomanufacturing

Pharmexa AB (Denmark; CSE:PHARMX)

Manufacturing agreement for Phase I supplies of a protein vaccine PX107 for treating bone disorders

The program will include cell banking, process development and GMP manufacture (2/7)**#



Expanded license agreement concerning the production of enterovirus assay kits

Competitive Technologies out-licensed the kits for the University of Colorado (4/13)

Crucell NV
(the Netherlands;

Talecris Biotherapeutics GmBH*

Long-term distribution deal under which Crucell will serve as the exclusive distributor of Talecris' Prolastin (alpha-1 proteinase inhibitor) in nine Western European countries

The deal is the first full use of Crucell's new pan- uropean marketing and sales organization (4/3)

Cytyc Corp.

Quest Diagnostics Inc. (NYSE:DGX)

Agreement for Cytyc to supply the ThinPrep Pap Test to Quest

The new agreement will run through the end of 2010; Quest also agreed to evaluate the ThinPrep Imaging System at certain laboratory sites (3/28)

Genta Inc.

IDIS World Medicines* (UK)

Distribution agreement for two of Genta's oncology products: Ganite and Genasense

The agreement covers all territories except the U.S. (3/7)


PharmAthene Inc.*

Agreement under which GTC will provide process development and clinical supply manufacturing services for PharmAthene's Protexia program

Protexia is a recombinant form of human butyrylcholinesterase produced in the milk of transgenic goats to treat victims of a chemical nerve agent attack (3/5)

Human Genome
Sciences Inc.

MedImmune Inc. (MEDI)

MedImmune is leasing a portion of an HGS manufacturing facility in Rockville, Md.

The pace will be used for development and manufacturing of clinical trial material for cell culture- based seasonal and pandemic influenza vaccine; terms of the deal were not disclosed (3/16)

Life Sciences

Tecpar* (Brazil)

Technology transfer and licensing agreement for Tecpar to manufacture a complex biopharmaceutical product for the Brazilian domestic market as well as all other South American countries

The total transaction is valued at C$19M (US$16.41M); ProMetic will receive about C$9M for license, milestone and development payments, and C$10M will go to modify Tecpar's current facility (3/22)

Senetek plc

Valeant Pharmaceuticals North America Inc. (NYSE:VRX)

Monetization agreement under which Senetek granted Valeant a paid-up license for Kinetin anti-aging active ingredient and Zeatin, a Kinetin analog

Senetek assigned Valeant future royalties from other Kinetin licensees; in return, Senetek will receive a cash payment of $21M, forgiveness of a $6M prepaid royalty credit reimbursement obligation and a right to share in future royalties due to Valeant from other Kinetin licensees through 2011 (4/2)


Blue Blood Biotech Corp.* (Taiwan)

Technical cooperation agreement for a development investigation into the mass production of recombinant NEFG protein

Blue Blood will pay Shanghai $400,000 for the work; the drug is being developed to treat diabetes patients (4/16)

Synco Bio
(the Netherlands)

Prosensa BV* (the Netherlands)

Collaboration for the formulation and fill of RNA- based therapeutics for Duchenne's muscular dystrophy

The agreement involves Prosensa's lead product, an RNA- based drug; terms call for SynCo to work with Prosensa to formulate and perform the aseptic fill of the product for use in a human trial (4/17)


Spectrumedix LLC*

Agreement under which Transgenomic will provide instrument service and consumables support in the U.S. and other areas for Spectrumedix products

Spectrumedix has ceased operations; Transgenomic has acquired certain assets and a license from Spectrumedix to manufacture consumables for the systems (4/12)

of Viragen Inc.;

Swedish Orphan International AB* (Sweden)

Licensing agreement for exclusive marketing rights to Multiferon for the European Union; it is approved in Sweden for malignant melanoma and other diseases

Viragen received about $2M up front and will serve as sole manufacturer for the product; Swedish Orphan will pay for Multiferon at an agreed-upon sales price, and Viragen will receive double-digit royalties on net sales (4/18)

* Private companies are indicated with an asterisk. ** Denotes the date the item ran in BioWorld International.
# Item occurred before the time frame of this chart but was not included in the previous chart.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; FSE = Franfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets.